Cell Line Development and Engineering US is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


March 9-12, 2020
Santa Clara Convention Center,
Santa Clara, California, USA

Revolutionize Cell Line Development & Engineering to Improve Product Quality, Reduce Timelines & Increase Titres

Leverage practical strategies to optimize CHO & novel cell lines, advance early clone selection & improve production of antibodies & complex molecules.

Co-location with BioProcess International US West 2020

Our team is excited to announce that next year's Cell Line Development and Engineering US meeting will be co-located with out BioProcess International US West 2020 meeting, held March 9-12, 2020 in Santa Clara, California.

Advance your cell line development

Cell Line Engineering: Improving The Host Cell
  • UC San Diego, Genentech, Pfizer, and Novartis will investigate the host cell; how do you manipulate established cell lines to achieve maximum results?

  • Merck and Biogen Research will uncover the latest genetic engineering approaches, including CRISPR, and how they are being utilized.
  • Overcome bioprocessing bottlenecks by engineering new host and vector designs.

  • Consider impacts of cell line development on early and late stage bioprocessing.
View Day 1 Agenda
Cell Line Development: Innovative Techniques & Technologies
  • Identify the latest clonal selection strategies to reduce timelines and achieve a high-quality product.

  • How are cutting-edge technologies being used in prediction, automation and high through-put approaches?

  • Discover the benefits of novel cell lines and discuss the pros and cons with CHO. Get involved in the interactive panel discussion featuring Sutro Biopharma, Glycotope, Biogen, Octapharma, and UC Davis.
View Day 2 Agenda
Coping with Clonal Stability & Complex Molecules
  • Keynote speaker Kristin Neuman, CRISPR Patent Attorney, will get you up to date on the legal and regulatory requirements when developing cell lines.

  • Achieve stable clones in an efficient and successful manner using genetic markers.

  • What are the best techniques for manufacturing complex molecules and biosimilars outside of traditional antibodies?
View Day 3 Agenda

Get the latest event updates

Sign up to get the latest event updates and information.

The Leading Cell Line Development Meeting

Meet, learn and network with over 250 scientists and academics
Over 25 New Data Sessions to Attend Across the Event
Hours of Dedicated Networking

Get Answers Now

  • Are there constraints for commercial human therapeutic applications of gene editing, given the current IP landscape? 
  • How important is the outcome of the patent interference (UC – U of Vienna vs. “Boston Biotech Cluster”) to the future of gene editing?
  • Are there uncertainties in translational research and clinical trials due to broad exclusive licenses over CRISPR technologies IP? 
  • Is CRISPR genome-editing know-how going to define future applications and further developments of it as nonobvious? 
  • Will commercial sublicenses be needed for follow-on applications of CRISPRC as technology? If so, when is this going to happen?


Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.  

(Companies A-L) Contact Jennifer Wickett: JWickett@knect365lifesciences.com | +1-857-504-6694 

(Companies M-Z) Contact Blake Shuka: BShuka@knect365lifesciences.com | +1-857-504-6684